BI Asset Management Fondsmaeglerselskab A S Grows Position in Alnylam Pharmaceuticals, Inc. $ALNY

BI Asset Management Fondsmaeglerselskab A S boosted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 121.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,869 shares of the biopharmaceutical company’s stock after acquiring an additional 8,164 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Alnylam Pharmaceuticals were worth $5,913,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. First Horizon Corp raised its holdings in shares of Alnylam Pharmaceuticals by 20.7% in the 4th quarter. First Horizon Corp now owns 163 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 28 shares in the last quarter. Yousif Capital Management LLC increased its holdings in Alnylam Pharmaceuticals by 1.8% in the fourth quarter. Yousif Capital Management LLC now owns 1,676 shares of the biopharmaceutical company’s stock valued at $666,000 after buying an additional 29 shares during the last quarter. Bessemer Group Inc. increased its holdings in Alnylam Pharmaceuticals by 15.6% in the third quarter. Bessemer Group Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 30 shares during the last quarter. Daiwa Securities Group Inc. raised its stake in Alnylam Pharmaceuticals by 0.3% in the second quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after buying an additional 35 shares in the last quarter. Finally, Everpar Advisors LLC lifted its holdings in Alnylam Pharmaceuticals by 6.3% during the 4th quarter. Everpar Advisors LLC now owns 620 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 37 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analysts Set New Price Targets

ALNY has been the subject of several analyst reports. Wall Street Zen raised Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a report on Monday, March 16th. Chardan Capital reiterated a “buy” rating and issued a $425.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, March 25th. Finally, HC Wainwright reissued a “buy” rating and set a $510.00 price objective on shares of Alnylam Pharmaceuticals in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $463.13.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $303.05 on Monday. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. Alnylam Pharmaceuticals, Inc. has a 52 week low of $283.10 and a 52 week high of $495.55. The business’s 50 day moving average is $307.66 and its two-hundred day moving average is $348.58. The firm has a market cap of $40.46 billion, a price-to-earnings ratio of 82.80 and a beta of 0.29.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating the consensus estimate of $0.87 by $1.12. The firm had revenue of $1.17 billion during the quarter, compared to the consensus estimate of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. Alnylam Pharmaceuticals’s revenue for the quarter was up 96.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.44) EPS. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.47 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, insider Melissa Mclaughlin sold 2,286 shares of the business’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $330.42, for a total value of $755,340.12. Following the transaction, the insider owned 9,443 shares in the company, valued at $3,120,156.06. The trade was a 19.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total value of $1,145,859.40. Following the sale, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 7,740 shares of company stock worth $2,420,214. Corporate insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.